145 related articles for article (PubMed ID: 21419444)
21. Use of hormonal therapy in men with metastatic prostate cancer.
Lu-Yao G; Moore DF; Oleynick J; Dipaola RS; Yao SL
J Urol; 2006 Aug; 176(2):526-31. PubMed ID: 16813882
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment staging of clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
Amis ES; Bigongiari LR; Bluth EI; Bush WH; Choyke PL; Fritzsche P; Holder L; Newhouse JH; Sandler CM; Segal AJ; Resnick MI; Rutsky EA
Radiology; 2000 Jun; 215 Suppl():703-8. PubMed ID: 11037488
[No Abstract] [Full Text] [Related]
23. A clinician-centred programme for behaviour change in the optimal use of staging investigations for newly diagnosed prostate cancer.
Rutledge AB; McLeod N; Mehan N; Regan TW; Ainsworth P; Chong P; Doyle T; White M; Sanson-Fisher RW; Martin JM
BJU Int; 2018 May; 121 Suppl 3():22-27. PubMed ID: 29359883
[TBL] [Abstract][Full Text] [Related]
24. Secondary cancer and relapse rates following radical prostatectomy for prostate-confined cancer.
Wesley D; Cox HF
J Insur Med; 2007; 39(4):242-50. PubMed ID: 18522141
[TBL] [Abstract][Full Text] [Related]
25. Cancers of the prostate, penis, and testicles: epidemiology, prevention, and treatment.
Stotts RC
Nurs Clin North Am; 2004 Jun; 39(2):327-40. PubMed ID: 15159183
[TBL] [Abstract][Full Text] [Related]
26. Unnecessary imaging for the staging of low-risk prostate cancer is common.
Lavery HJ; Brajtbord JS; Levinson AW; Nabizada-Pace F; Pollard ME; Samadi DB
Urology; 2011 Feb; 77(2):274-8. PubMed ID: 20932557
[TBL] [Abstract][Full Text] [Related]
27. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
28. A new formula for prostate cancer lymph node risk.
Yu JB; Makarov DV; Gross C
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):69-75. PubMed ID: 20594769
[TBL] [Abstract][Full Text] [Related]
29. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
[TBL] [Abstract][Full Text] [Related]
30. Some comments and data on the overtreatment of prostate cancer.
Schulz RJ; Kagan AR
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):690-1. PubMed ID: 15380613
[No Abstract] [Full Text] [Related]
31. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
32. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.
Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE
Urology; 1995 Sep; 46(3):277-89. PubMed ID: 7544931
[No Abstract] [Full Text] [Related]
33. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
Stone NN; Stock RG
Mt Sinai J Med; 1999 Jan; 66(1):26-30. PubMed ID: 9989102
[TBL] [Abstract][Full Text] [Related]
34. Utilizing the tumor-node-metastasis staging for prostate cancer: the sixth edition, 2002.
Chang SS; Amin MB
CA Cancer J Clin; 2008; 58(1):54-9. PubMed ID: 18096866
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients.
Potosky AL; Merrill RM; Riley GF; Taplin SH; Barlow W; Fireman BH; Lubitz JD
Health Serv Res; 1999 Jun; 34(2):525-46. PubMed ID: 10357289
[TBL] [Abstract][Full Text] [Related]
36. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer: a review of common underwriting problems, part 2.
Richie RC; Swanson JO
J Insur Med; 2004; 36(4):310-9. PubMed ID: 15683209
[TBL] [Abstract][Full Text] [Related]
38. Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States.
Le A; Berger D; Lau M; El-Serag HB
Ann Surg Oncol; 2007 Sep; 14(9):2519-27. PubMed ID: 17610016
[TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
40. Clinical and diagnostic assessment for therapeutic decisions in prostate cancer.
Passoni NM; Di Trapani E; Suardi N; Gallina A; Abdollah F; Bianchi M; Picchio M; Giovacchini G; Messa C; Rigatti P; Montorsi F; Briganti A
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):321-30. PubMed ID: 23013662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
